...Research Paper AstraZeneca Pharmaceuticals, (AZN) is one of the world's leading pharmaceutical companies with 57,000 employees worldwide in over 100 countries. Its corporate headquarters are in London, research and development headquarters are in Södertälje, Sweden, and its manufacturing facilities employ 9,600 people in 16 different countries. The company operates fourteen research and development sites in eight countries and has sales in over 100 countries around the world. AstraZeneca focuses its pharmaceutical business on seven key therapeutic areas: anesthesia and pain control, cardiovascular, central nervous system, gastrointestinal (it is a world leader in this therapeutic area), infection, oncology, and respiratory. Its product range includes such blockbusters as Nexium, Crestor, Seroquel, and Symbicort. AstraZeneca was formed as the result of the 1999 merger of two European pharmaceuticals companies: Astra AB of Sweden, a maker of pharmaceutical products and medical devices, and Zeneca PLC of the United Kingdom, a bioscience company focusing on pharmaceuticals, agricultural and specialty chemicals, and disease-specific healthcare services. One year after its merger, the company achieved sales of US$15.8 billion, with an operating profit of US$4 billion. In 2011, company sales and operating profit were $33.6 billion and $13.2 billion respectively. AstraZeneca is one of the world's largest pharmaceutical companies, with FY2011 sales of $33.27 billion and $10...
Words: 1230 - Pages: 5
...Introduction: 1 Task: 1 1 (a) Ratio analysis on the basis of AstraZeneca Annual Report and Form 20-F Information 2012: 1 (b) Business structure and financial structure (comparison and relative advantages of the chosen organization) 5 (c) Compare and comment on the finances of business: 7 (d)Recommend potential investor for the investment decision: 8 (e)All possible Sources of finance for 500000 and best source 8 (f) Management of working capital: 10 Task 2: 11 (a)Preparations of a cash flow forecast and comment on budget and cash flow: 11 (b)Recommendation for managing cash flow: 12 Task 3: 12 (a)Assessment of projects by financial techniques: 12 (b) Recommendation from the above calculations and reason behind the choice: 13 Conclusions: 14 Reference: 15 Introduction: Finance is the paramount part of every organization. Whatever the size of the company, financing plays a vital role in the business organization. Ratio analysis is an important tool for the business decision as well as for the interpretation of the financial statements. We have selected AstraZeneca Annual Report & form 20-F information 2012. All the ratio analysis and decision in respect of the business structure as well as financial structure are based on this particular company. Investment appraisal techniques like- NPV, internal rate of return, payback period, accounting rate of return are based on the given data. This report suggests appropriate decision with the analysis on the basis of...
Words: 3459 - Pages: 14
...A critical analysis of AstraZeneca plc.’s shareholder wealth creation in the five-year period from 2010-15 * Xiaoyu Zhang August 2016 MSC in Accounting and Financial Management Global Pharmaceutical Industry Overview Pharmaceutical industry is closely bound up with people’s living standard, which also correlates general economic and deserves thoroughly research and analysis. Due to favorable demographic trends and significant unmet medical needs, the pharmaceutical industry is expected to enjoy long-term growth. According to the research conducted by AstraZeneca, there is 9.5% growth in 2015 of global pharmaceutical sales (AZ annual report 2015, p12). The number of people accessing healthcare is increasing, as is healthcare spending, particularly by the elderly. For example, WHO estimated that, by 2050, the world’s population aged 60 years and older is expected to total two billion, up from 900 million in 2015 and that, by then, 80% of all older people will live in low- and middle-income countries. Emerging markets are expected to continue to boost pharmaceutical growth. Furthermore, the increasing threat of non-communicable diseases (NCDs), such as cancer and cardiovascular, metabolic and respiratory diseases, has killed tens of millions of people. It is estimated that NCDs kill 38 million people each year and especially affect low- and middle-income countries where nearly three-quarters of these deaths occur (WHO, 2011). As reported, NCDs are often associated...
Words: 5872 - Pages: 24
...Strategic Analysis of Syngenta Jolly was a young, bright girl, studying her Bachelor of Business Administration. When she came home from college, her mind was occupied by the assignment given to her in her Business Strategy Class. She had to pick up a company of her choice and complete strategic analysis, over a period of three years, consisting of size of the organization, financial performance, operational performance, some tailored measures of performance relating to the organization’s industry, competitor analysis, strategic actions of the organization, and strategic issues faced. She thought that she would figure out what procedure to follow from her prescribed textbook ‘Strategic Management – Theory and Application,’ by Adrian Haberberg & Alison Rieple. After a certain thought, she chose Syngenta – headquartered at Basel, Switzerland. Jolly referred to the textbook and jotted down the procedure as below. Procedure for doing the Strategic Analysis: 1) Evaluate financial performance: Calculate the following quantities and analyze them and find out the trend in the last three years. Overall Sales Overall Profit Profitability ratios such as Return on Equity (ROE), Return on Assets (ROA), and Return on Capital Employed(ROCE). 2) Measure operational performance: Page 1 of 29 Calculate the following quantities; find out the trend and analyze: Operating profit Operating profit as a percentage of sales (profit margin) Sales per employee Operating profit per employee ...
Words: 6884 - Pages: 28
...| Pfizer Stock Report | | Fall 2013 Research Project | | Pfizer Stock Report | | Fall 2013 Research Project | Saint Joseph’s University Contents II. Introduction 2 III. Macroeconomic Review 3 IV. Stock Market Analysis 6 V. Industry Analysis 8 VI. Company Strategic Analysis 10 VII. Company Financial Analysis 12 VIII. Application of Valuation Methodologies 13 IX. Conclusion and Recommendations 15 X. Exhibits 16 A. Exhibit A 17 B. Exhibit A 17 XI. References 18 Introduction Pfizer, headquartered in New York, NY, is committed to applying science and global resources to improve the health and well-being of individuals of all stages of life. Ian Read, CEO, leads the company through innovation and solid long term performances on the NYSE. Pfizer is also on the London, Euronext and Swiss exchanges. They make every effort to provide everybody with access to affordable, top of the line, safe remedies and health related services to those in need. Some of Pfizer’s most famous products include, Lipitor, Lyrica, Diflucan, Zithromax, Viagra, and Celebrex. Pfizer is committed to providing sustainable solutions to the biggest health issues in the world by continuously reviewing and updating their products and services to reduce their environmental footprints. The company maintains the highest ethical standards in all that they do such as sales and marketing to research and development. Pfizer, along with all industry...
Words: 4411 - Pages: 18
...Liquidity Ratios Current ratio Pfizer’s current ratio in 2011 (up to September 31, 2011) was 2.25. This means that the company has $2.25 in its current assets to pay $1 of it current liabilities. In general, Pfizer is increasing this ratio over the last 4 year from 1.59 in 2008 to 2.25 in 2011. It is also in line with the industry performance. The main reason for this gradual increase is the fact that Pfizer is accumulating current assets of acquired companies. For example, in 2009-2010 Pfizer acquired Wyeth together with Wyeth’s taxes and other Wyeth's current assets totaling to $1.2 billion (Pfizer, 2010). Cash and cash equivalents also increased in 2011 due to the fact that Pfizer needs cash on hands to settle ongoing acquisition of King (Pfizer, 2010). At the same, the time growth in accounts receivables from $14.4 billion to $15.7 was caused by higher sales in 2011 for the same nine month period ($50.6 billion in 2011 vs. $49.7 billion in 2010) Quick ratio In 2011 for nine month period Pfizer had 1.9 quick ratio. This means that for each dollar Pfizer owes, the company has $1.9 in its cash, cash equivalents, marketable securities, and accounts receivables to pay back. Inventory amount is excluded from calculation. In case the company is about to be liquidated or default, inventory cannot be quickly sold to get cash for it. Pfizer is doing very well with respect to the quick ratio. The company is improving it over the period of last four years. The main reason for it is...
Words: 1551 - Pages: 7
...Topic: Pfizer’s approach to segmentation using Lipitor as an example. What is market Segmentation? Segmentation is a process of processing a large homogenous market into clearly defined identifiable segments with a main aim of designing a marketing mix to match target customers expectations. The basic factors that affect market segmentation are: [1] a) Clear identification of segment b) Determining the effective size of segment c) Promotion of the product to segments d) Using appropriate policies and resources of firm There are few main basic strategies that influence pharmaceutical customer segmentation. They are: a) Demographic ( age, income, sex etc) b) Socio-economic ( social class, stage in family life cycle) c) Geographic factors d) Psychological factors (lifestyle, personality traits) Other factors include perceptual, brand loyalty patterns and medical condition. [2] Segmentation of market is one of the crucial elements of marketing strategy. Criteria depend mainly on nature of market, therefore creating a problem in deciding the actual method. Maslow hierarchy of needs also explains about satisfying the customer needs in a vertical arranged pyramid with primary psychological needs at the bottom step and with self-actualization needs at highest step with safety needs, belonging needs and esteem needs as intermediate steps in the hierarchy. For my research, I have chosen Pfizer and will explain its...
Words: 1436 - Pages: 6
...COUNTRY ANALYSIS REPORT: MEXICO VS U.S.A HEALTHCARE MERCK - DIABETES Group 14 – Campus Santa Fe: Angelica Hidalgo 1461526 Alejandro Meza 1464801 Cinthia Merlos 1462113 Juan José Ibarra 1465263 April 10th, 2012 INDEX 1. INTRODUCTION 2. ECONOMIC VARIABLES 3. POLITICAL VARIABLES 4. SOCIO –CULTURAL AND DEMOGRAPHIC VARIABLES 5. COUNTRY ATTRACTIVENESS SCORE 6. THE DECISION 7. EXHIBITS 8. BIBLIOGRAPHY 1. INTRODUCTION 2. ECONOMIC VARIABLES The total economic impact of diabetes worldwide In the world the economic impact about the diabetes was 376 billion dollar in 2010, this is the 11.6% of the total healthcare budget in the world. This facts give us an idea about how is important to analyze the impact in economies of this disease and we are going to go deeper for the analysis of Mexico and United States of America. MEXICO In Mexico the economic impact due to diabetes cost more than 7 billion dollars in 2011 according to the Instituto Nacional de Salud Publica. And is expected an increase of 15% this year of 2012 this impact is really huge because 50% of this expense was made by families and the other 50% was made by government in Latin America Mexico is the country...
Words: 4412 - Pages: 18
...PORTFOLIO MANAGER’S REVIEW A Monthly Publication of BeyondProxy LLC September 30, 2010 Subscribe at www.manualofideas.com When asked how he became so successful, Buffett answered: “we read hundreds and hundreds of annual reports every year.” Edited by the Manual of Ideas Research Team “If our efforts can further the goals of our members by giving them a discernible edge over other market participants, we have succeeded.” Top Five Ideas In This Report Lavendon (London: LVD) ………………… p. 16 Nokia (Helsinki: NOK1V, NYSE: NOK) .. 20 OMV (Vienna: OMV, OTC: OMVKY) …. 24 OPAP THE EUROPEAN VALUE ISSUE ► Snapshot of 100 European value opportunities ► 45 European “magic formula” companies ► 45 book value bargains by country ► 20+ companies profiled by MOI research team ► Top 5 ideas, based on proprietary MOI methodology ► Plus: Superinvestor holdings update ► Plus: Favorite stock screens for value investors ► Plus: Exclusive interview with Ciccio Azzolini (Greece: OPAP, OTC: GOFPY) .. 28 Premier Foods (London: PFD, OTC: PRRFY) ….. 32 Also Inside Editor’s Commentary …………….. p. 4 Superinvestor Holdings Update …. p. 9 45 European MF Companies …… p. 10 Interview: Ciccio Azzollini ……… p. 12 Top 5 European Ideas ……………p. 16 Other European candidates …….. p. 36 Euro Book Value Bargains ……. p. 100 100 Cheap European ADRs …….p. 114 About Portfolio Manager’s Review Our goal is to bring you investment ideas that are compelling...
Words: 8940 - Pages: 36
...Equities 27 March 2014 │ 20 pages Western Europe New UK Auditor’s Reports A Review of the New Information What's New — UK auditor’s reports became (a bit more) interesting this year. Auditors are now required to provide company-specific information in their reports. We have reviewed some of the new reports and summarise key conclusions here. 3 new pieces of information: — Auditors are required to report on the materiality for the audit, the scope of the audit, and the work done on key areas of audit focus (ie key risks). Sarah Deans +44-20-7986-4156 sarah.deans@citi.com Terence Fisher +44-20-7986-5180 terence.fisher@citi.com Materiality typically 5% of PBT — Information is material if “omitting it or misstating it could influence decisions that users make on the basis of financial information”. The materiality amount is used by the auditor in planning and performing the audit and when assessing whether the financial statements give a true and fair view. In 78% of cases, materiality has been calculated as a percentage of pre-tax profit, usually around 5%, but sometimes as high as 10%. In our view, many analysts and investors will be surprised at this relatively high level of materiality. Large variation in length and quality — Reports we reviewed varied in length from 2 to 7 pages. We also noted very significant variations in quality, with some reports adding little or no value with largely boilerplate comments, while others ...
Words: 14003 - Pages: 57
...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth discussion...
Words: 5468 - Pages: 22
...(2014, April 5). The Awful Truth Behind the Gender Gap. Retrieved October 9, 2015. 5. Smith, K. (2014, April 10). The Gender Pay Gap Is Just the Beginning of America's Pay Inequity Problem. Retrieved October 9, 2015. 6. The Simple Truth about the Gender Pay Gap (Fall 2015) (AAUW: Empowering Women Since 1881) 7. Mind the Gap: How One Employer Tackled Pay Equity. (n.d.). Retrieved October 9, 2015. 1. It’s no secret that women are paid less than men, even when occupations are held constant, and even when those occupations are high-pay and high-skill. According to the Bureau of Labor Statistics, the median weekly earning for American female physicians working full-time is $1,497, while for men it is $2,087. A 2013 BLS report shows pay inequity by occupation for women of all races: women in architecture and engineering occupations earn 83.7% to the dollar in comparison to men and in computer and mathematical occupations 81% to the dollar in comparison to men. When Forbes analyzed 2012 median weekly earnings of full-time wage and salary workers data from BLS for the top-paying professions, they found that women earned on average approximately 83% to every dollar made by men. Since choosing a STEM profession or climbing the corporate ladder simply guarantees a higher salary, not an equitable one, how can pay equity be achieved? Much of the recent media focus on this issue has covered what women can personally do to close the pay gap. Clearly, women do need to...
Words: 5900 - Pages: 24
...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth discussion...
Words: 5468 - Pages: 22
...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be...
Words: 5468 - Pages: 22
...Fourth Edition Financial Statement Analysis & Valuation Peter D. Easton University of Notre Dame Mary Lea McAnally Texas A&M University Gregory A. Sommers Southern Methodist University Xiao-Jun Zhang University of California, Berkeley Cambridge Business Publishers To my daughters, Joanne and Stacey —PDE To my husband Brittan, and my children Loic, Maclean, Quinn and Kay —MLM To my wife Susan, and my children Christian, Peter and Philip —GAS To my wife Sharon, my daughter Jasmine, and my parents 滕惠清 and 张祥林 —XZ Financial Statement Analysis & Valuation, Fourth Edition, by Peter D. Easton, Mary Lea McAnally, Gregory A. Sommers, and Xiao-Jun Zhang. COPYRIGHT © 2015 by Cambridge Business Publishers, LLC. Published by Cambridge Business Publishers, LLC. Exclusive rights by Cambridge Business Publishers, LLC for manufacture and export. ALL RIGHTS RESERVED. No part of this publication may be reproduced, distributed, or stored in a database or retrieval system in any form or by any means, without prior written consent of Cambridge Business Publishers, LLC, including, but not limited to, in any network or other electronic storage or transmission, or broadcast for distance learning. Student Edition ISBN 978-1-61853-104-9 Bookstores & Faculty: to order this book, call 800-619-6473 or email customerservice@cambridgepub.com. Students: to order this book, please visit the book’s Website and order directly online. Printed in...
Words: 28387 - Pages: 114
